Free Trial
NASDAQ:ALGS

Aligos Therapeutics Q4 2023 Earnings Report

Aligos Therapeutics logo
$10.25 -0.81 (-7.32%)
As of 01:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aligos Therapeutics EPS Results

Actual EPS
-$5.50
Consensus EPS
-$6.75
Beat/Miss
Beat by +$1.25
One Year Ago EPS
N/A

Aligos Therapeutics Revenue Results

Actual Revenue
$2.68 million
Expected Revenue
$3.20 million
Beat/Miss
Missed by -$520.00 thousand
YoY Revenue Growth
N/A

Aligos Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Tuesday, March 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Aligos Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Thursday, November 6, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aligos Therapeutics Earnings Headlines

Equities Analysts Set Expectations for ALGS Q3 Earnings
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
See More Aligos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email.

About Aligos Therapeutics

Aligos Therapeutics (NASDAQ:ALGS), a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

View Aligos Therapeutics Profile

More Earnings Resources from MarketBeat